Liver and Bile Duct Cancer [Hepatobilliary Cancer]

The Recanati/Miller Transplantation Institute (RMTI), part of The Mount Sinai Health System in New York City, offers the most comprehensive, state-of-the art services available to patients with confirmed or suspected liver and bile duct (hepatobiliary) cancers.

At RMTI, we diagnose, treat, and manage primary liver and bile duct cancer (cancer that begins in the liver or bile ducts) at the full range of potential stages, including early stage and end stage disease. We also diagnose, treat, and manage potentially pre-cancerous liver conditions.

Outstanding Services and Multidisciplinary Approach

Using a multidisciplinary approach, we tackle the often challenging nature of liver and bile duct cancer, determining the appropriate diagnosis and tailoring the best treatment option to the unique needs of each patient. We do this by bringing together an extraordinary team of experts, who draw on years of experience in surgical oncology, gastroenterology, pathology, radiation, radiation oncology, critical care, and transplant immunology. These specialists meet together weekly to discuss the needs of each patient and most effective treatment options.

Among the other outstanding services and treatment options we offer are:

  • Advanced screening and diagnostic techniques, including non-invasive imaging techniques by radiologists who specialize in liver cancer.

  • Less invasive laparoscopic surgeries to remove small tumors, as well as highly complex liver resections.

  • Liver transplantation, which may be recommended as a treatment option. Mount Sinai’s Adult Liver Transplant Program is one of the oldest and largest in the country, and our highly skilled liver transplant surgeons are among the most accomplished in the nation.

  • Live donor liver transplantation, including split liver transplantation, in which one donor’s liver is split in two to save two people. The Zweig Family Center for Living Donation at Mount Sinai, the first such center of its kind, provides medical, surgical, and psychological expertise to people considering living donation or who have already donated.

At the Forefront of Liver Cancer Research

As a leader in researching new treatments, we are often able to offer our patients access to innovative therapies through clinical trials before they are available anywhere else. Mount Sinai was the largest patient recruitment site in the country for studies of the drug sorafenib (Nexavar®), the first treatment proven to extend life for patients with advanced liver cancer.

Transplant Living Center

With amenities including ten bedrooms and two kitchens, the Transplant Living Center (with concierge Allyson Reala) is a "home away from home" for patients and families.